News

MorphoSys would receive payment from Centocor Ortho Biotech in connection with the initiation of a phase-I clinical trial, using a HuCAL-derived, fully human antibody in the therapeutic area

Amarillo (ABI) and CytoPharm have started the enrollment for a study of ABI’s oral interferon-alpha lozenges, for chronic hepatitis-C virus infection. The aim of the trial is to

CytRx has provided a favorable progress update for its ongoing Phase 2 STAR-1 registration clinical trial, to evaluate the efficacy and safety of orally administered tamibarotene as a

Rexahn has signed an exclusive collaboration and option for license agreement with the Partner Co., for the development of RX-3117. RX-3117 is a small molecule, new chemical entity

Palkion has initiated preclinical development studies for orally available anemia therapeutic candidate, that modulates the Hypoxia-Inducible factor Prolyl Hydroxylase (HIF-PH) enzyme system. CrystalGenomics would use its structure-based drug

Juvaris has signed an agreement with Antigen Discovery (ADi) to access ADi’s high-throughput protein microarray screening system to discover novel disease-specific antigens. Juvaris will sponsor research for multiple

Biovest, a subsidiary of Accentia Biopharmaceuticals, has announced that BiovaxID, a personalized therapeutic anti-cancer vaccine, is available on a named-patient basis in Europe. A named-patient program is a

Takeda Global Research and Development Center has received a complete response letter from FDA, regarding the new drug application (NDA) for alogliptin. Its a selective dipeptidyl peptidase IV

GlaxoSmithKline (GSK) announced that the Commercial Court in Dublin, Ireland, has ruled in patent litigation regarding GSK’s Seretide, an inhaled respiratory treatment for asthma and COPD. Justice Charleton